Market Research Reports- Consulting Analysis Crystal Market Research Deep Brain Stimulation Market by Application - Glo | Page 2

Parkinson’s disease segment accounted for more than three-fourth share of the global DBS market in
2016, due to growing prevalence of this disease. According to the Parkinson’s Disease Foundation,
around 60,000 patients are diagnosed with Parkinson’s disease every year in the U.S. Men are one and a
half times more susceptible to Parkinson’s disease as compared to women. Although DBS is not a
permanent cure for Parkinson’s disease it can surely control the symptoms to a great extent improving the
quality of life of the affected patients. According to WHO, more than 50 million people across the world
are suffering from epilepsy. DBS has significant applications in the treatment of epilepsy by reducing the
chances of a seizure.
North America held a significant share of the global deep brain stimulation market in 2016, due to the
presence of major vendors in the U.S. and advanced healthcare research and development facilities
conducting research on the treatment of neurological diseases. The Asia-Pacific DBS market will show
considerable growth during the forecast period. Deep brain stimulation procedure acts as a minimally
invasive alternative to long term administration of medication for Parkinson’s patients. This could be
beneficial with respect to affordability for patients in emerging economies.
Request a sample copy of Deep Brain Stimulation Market Research Report @
http://www.crystalmarketresearch.com/report-sample/HC058
Some of the key players in DBS market are St. Jude Medical, Medtronic Plc., Enteromedics, Boston
Scientific Corporation, Aleva Neurotherapeutics SA, Zynex, and Cyberonics. These players focus on
strategic acquisitions to expand their product portfolio and sustain their positions in the market. For
instance, in August 2014, Medtronic acquired Sapiens Steering Brain Stimulation, to strengthen its
capabilities to carry out more precise stimulation of intended target in the brain.
Key Findings of the Research Study:



Patient’s suffering from Parkinson’s disease experience improved motor functions as a result of
DBS. People affected by epilepsy who are not suitable candidates for respective surgery, witness
significant reduction in seizures.
Parkinson’s disease market held a major share of the global DBS market due to the benefits
offered by DBS for controlling the symptoms of Parkinson’s disease and allowing the patients to
lead a better life with improved mobility.
North America dominated the global DBS market in 2016, due to high adoption of
technologically advanced products and availability of advanced healthcare infrastructure.